Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient? - Archive ouverte HAL Access content directly
Journal Articles Advanced Drug Delivery Reviews Year : 2022

Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient?

Abstract

Respiratory diseases gather a wide range of disorders which are generally difficult to treat, partly due to a poor delivery of drugs to the lung with adequate dose and minimum side effects. With the recent developments of nanotechnology, nano-delivery systems have raised interest. In this review, we detail the main types of nanocarriers that have been developed presenting their respective advantages and limitations. We also discuss the route of administration (systemic versus by inhalation), also considering technical aspects (different types of aerosol devices) with concrete examples of applications. Finally, we propose some perspectives of development in the field such as the nano-in-micro approaches, the emergence of drug vaping to generate airborne carriers in the submicron size range, the development of innovative respiratory models to assess regional aerosol deposition of nanoparticles or the application of nano-delivery to the lung in the treatment of other diseases.
Fichier principal
Vignette du fichier
2022_HAL_ Forest et al_ADDR.pdf (676.63 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-03610343 , version 1 (16-03-2022)

Identifiers

Cite

Valérie Forest, Jérémie Pourchez. Nano-delivery to the lung - by inhalation or other routes and why nano when micro is largely sufficient?. Advanced Drug Delivery Reviews, 2022, 183, pp.114173. ⟨10.1016/j.addr.2022.114173⟩. ⟨hal-03610343⟩
24 View
740 Download

Altmetric

Share

Gmail Facebook X LinkedIn More